Study of a drug for stroke patients after blood clot treatment
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests if adding a drug called human urinary kallidinogenase (HUK) can improve recovery for people who have had a stroke and already received clot-busting medicine or a procedure to remove the clot. The goal is to see if it helps reduce disability after a stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a stroke affecting the front part of the brain within the last 24 hours.
- Your stroke symptoms are moderate to moderately severe (NIHSS score 4 to 25).
- You already received clot-busting medicine or a procedure to remove the clot.
- You were able to do daily activities on your own before the stroke.
- You do not have a history of bleeding problems, liver or kidney disease, or recent use of certain blood thinners or blood pressure medicines.
- You are not allergic to the study drug or related medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the clot-busting drug urokinase can help people who have had an ischemic stroke (a stroke caused by a blood clot). The goal is to dissolve the clot and improve recovery, as long as treatment starts within 6 hours of the first symptoms.
This trial tests whether a medicine called human urinary kallidinogenase can reduce inflammation after a stroke. It may help people who have had a first or recent stroke and have certain levels of disability.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
This trial tests whether adding a medicine called human urinary kallidinogenase (which improves blood flow to the brain) to standard clot-busting treatment (reteplase) helps people recover better from an acute stroke. It's for patients who arrive at the hospital within 4.5 hours of symptom onset and meet specific safety criteria.
This trial tests whether a drug called urinary kallidinogenase can help people who have had a stroke caused by a blocked artery in the brain. The drug is given within 48 hours of the stroke, and the study hopes to see if it improves recovery and reduces disability.
This trial tests whether an experimental medication called human urinary kallidinogenase can help people recover better and faster after a recent stroke. The medication is given as an injection and is thought to improve blood flow to the brain, potentially helping with movement and daily function.
Hear when a new Acute Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.